Abstract:BACKGROUND:Cyclo-oxgenase 2 (COX-2) is involved in prostaglandin synthesis in central nervous system, and it also plays a role in human carcinogenesis. Our purpose of this study is to investigate the COX-2 expression in different development stages of colorectal cancer, and to discuss the relationship between the gene expression and clinicopathological features of the cancer.METHODS:COX-2 expression was examined by immunohistochemical staining in 76 surgical specimens of colorectal cancer (44 of advanced stage and 32 of early stage), thirty-three adenomas and 18 normal colonic mucosal tissues taken by endoscopic biopsy. Kaplan-Meier survival curves and Cox proportional hazards regression were used to evaluate the relation of COX-2 to prognosis.RESULTS:COX-2 expression, divided into 4 grades from "-" to "+++", is respectively 83.3%, 16.7%, 0% and 0% in normal colonic mucosal tissues; 12.1%, 42.4%, 36.4% and 9.1% in adenomas; 6.3%, 28.1%, 46.9% and 18.7% in early colorectal cancers (ECCs), and 6.8%, 20.5%, 18.2% and 54.5% in advanced colorectal cancers (CRCs). The differences in COX-2 expression between advanced CRCs and early colorectal cancers (ECCs) as well as between the advanced CRCs and adenomas were statistically significant (P < 0.01); but there was no significant difference between ECCs and adenomas. Kaplan-Meier survival analysis showed a significant difference in the survival curves between low high COX-2 groups (P < 0.05). Cox proportional hazards regression showed that COX-2 expression was related to poorer long-term outcome with a hazard ratio of 2.665 unadjusted for other variables (P < 0.05), and COX-2 expression was an independent risk factor of poor prognosis.CONCLUSIONS:COX-2 expression is gradually up-regulated in the development from normal epithelium to adenomas and from ECCs to advanced CRCs. Alhough the COX-2 protein can not be regarded as a tumor marker to diagnose CRCs early, COX-2 expression can be regarded as an independent risk factor of poor prognosis for postoperative patients with advanced CRCs.

Expression of cyclooxygenase-2 in pancreaticcancer and its correlation with p53

Expression of cyclooxygenase 2 in colorectal cancer

Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.

Cyclooxygenase-2 Expression Is Up-Regulated In Human Pancreatic Cancer

Cyclooxygenase-2 Expression and Its Correlation with Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma

Expression of P53, P16 and Cyclooxygenase-2 in Esophageal Cancer with Tissue Microarray

[Detection of Expression of P53, P16, and Cyclooxygenase 2 in Pancreatic Cancer by Tissue Microarray and Correlation among These Three Genes].

[Expression of Tissue Microarray P53, P16 and Cyclooxygenase-2 in Gastric Cancer].

Expression of the cyclooxygenase-2 gene and its clinical significance in non-small cell lung cancer

Expression of iNOS and COX-2 in pancreatic adenocarcinoma and its clinical significance

Expression and Significance of P53 and Bcl-2 Protein Pancreatic Adenocarcinoma

Relationship Between COX-2 Expression and Clinicopathological Features of Colorectal Cancers

Relationship between cyclooxygenase-2,p53 and microvascular density and lymph node metastasis in breast carcinoma

Cyclooxygenase-2 expression correlates with angiogenesis and vascular endothelial growth factor-A in non-small cell lung cancer

Expression of Cyclooxygenase-2 in Colorectal Cancer and Its Clinical Significance

Association Between Cyclo-Oxygenase-2 Overexpression and Missense P53 Mutations in Gastric Cancer

Expression of COX-2 and p53 protein in esophageal carcinoma and their significance

Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis

Correlation of Expression of COX-2 to Clinical Pathological Characters and Its Catalytic Products in Gastric Carcinoma

Expressions of COX-2 and MMP-2 in Colon Cancer Tissues and Its Significance

Researches of Cyclooxygenase-2 Expression in Lung Cancer Tissues and Its Correlation with the Clinicopathological Features of Lung Cancer Patients